openPR Logo
Press release

The Non Melanoma Skin Cancer Market to Ride on Video Storytelling

The Non Melanoma Skin Cancer Market to Ride on Video Storytelling

The Non Melanoma Skin Cancer Market is all set to go great guns in the forecast period. Big data makes way for real-time data visualization, thereby identifying the high-risk populations. Healthcare organizations are into sharing more data. This creation and collection of bigger datasets are likely to increase precision and help organizations in spotting trends. These trends are expected to keep the entire healthcare vertical on the toes.

In a new report titled 'Non-Melanoma Skin Cancer Treatment Market: Global Industry Analysis 2012 - 2016 and Forecast 2017 - 2025,' Persistence Market Research analyzes the global non-melanoma skin cancer treatment market over an eight year forecast period 2017 - 2025 and throws light on the various factors impacting revenue growth of the market over the said period. The report highlights the market forecasts for the different segments and presents deeper insights for informed decision making.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3648

Company Profiles

Almirall S.A.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Elekta AB
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
Mylan NV
Sun Pharmaceutical Industries Ltd.
Varian Medical Systems, Inc.
Sensus Healthcare
iCAD, Inc.
Accuray, Inc.
Ion Beam Applications SA
Others.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/3648

Region - High Prevalence of Non-Melanoma Skin Cancer in North America

North America is estimated to hold a market share of roughly 55% in the global non-melanoma skin cancer treatment market in 2017 and is anticipated to have the highest attractiveness index of 3.0 during the forecast period. Non-melanoma skin cancer is more prevalent in senior citizens and the Population Reference Bureau estimates that Americans over the age of 65 will double to almost 100 million by 2060.

Treatment Type - Radiation Therapy Larger than Chemotherapy and Photodynamic Therapy

Radiation therapy is larger than chemotherapy and photodynamic therapy combined, making it imperative for key stakeholders in the non-melanoma skin cancer treatment market to focus on this treatment type. Radiation therapy is poised to be worth more than US$ 4.7 Bn by end 2025. Within radiation therapy, companies may wish to target superficial radiation therapy.

Indication - Basal Cell Carcinoma Dominates the Non-Melanoma Skin Cancer Treatment Market

Even though squamous cell carcinoma is predicted to record a higher CAGR of 6.4% from 2017-2025, it is unlikely to outpace basal cell carcinoma anytime soon as the latter is likely to value at approx. thrice the size of the former by end 2025. The attractiveness index of basal cell carcinoma is 1.5, considerably larger than the 0.5 of squamous cell carcinoma during the same period.

End User - Hospitals Popular Channel in the Non-Melanoma Skin Cancer Treatment Market

The treatment modalities for non-melanoma skin cancer usually require expensive radiation therapy. Therefore, hospitals are preferred over ambulatory surgical centers and specialty clinics in the non-melanoma skin cancer treatment market. The hospital segment is expected to reach a value of US$ 2 Bn in 2017 itself.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/3648

Key Findings of the Non-Melanoma Skin Cancer Treatment Market Report

Non-melanoma skin cancer places a high economic burden on countries with minimal medical treatment options, particularly at the metastatic stage. Many pharmaceutical companies are now trying to develop treatment options for late-stage non-melanoma skin cancer. In addition, companies seek to use their existing drugs to effectively tackle squamous cell and basal cell carcinoma. Major players such as Bristol-Myers Squibb, Genentech, and Merck are working on gaining approval for their drugs to treat non-melanoma skin cancer.

Regulatory authorities and governmental bodies worldwide are adopting a number of cost-containment measures in the developed world. They are shifting from a volume to value-based system and this is driven by steps taken by life sciences companies and governments. The measures include profit and risk sharing, outcome-based pricing, competitive tendering, and price control.

The value-based healthcare system strives to achieve maximum value for every dollar spent on healthcare and improve outcomes by way of integrated care pathways. The system simultaneously levies pricing pressure on medtech and biopharmaceutical companies and could potentially impact R&D investment in crucial, lifesaving medical treatment technologies in the long run.

Access Related Reports-

Dental Implants Market: https://www.persistencemarketresearch.com/market-research/dental-implants-market.asp

Regenerative Therapies Market: https://www.persistencemarketresearch.com/market-research/regenerative-therapies-market.asp

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Non Melanoma Skin Cancer Market to Ride on Video Storytelling here

News-ID: 2567558 • Views:

More Releases from Persistence Market Research

Fruit Ingredients Market to Reach US$ 111.3 Bn by 2032, Driven by Rising Health Trends
Fruit Ingredients Market to Reach US$ 111.3 Bn by 2032, Driven by Rising Health …
Overview of the Global Fruit Ingredients Market The global fruit ingredients market is witnessing significant growth, driven by rising consumer demand for natural, clean-label, and nutrient-rich food products. In 2025, the market is likely to be valued at US$ 75.0 billion and is expected to reach US$ 111.3 billion by 2032, registering a robust CAGR of 5.8% during the forecast period. Fruit ingredients, which include fruit concentrates, purees, powders, and extracts,
Vegan Dessert Market to Reach US$ 11.9 Bn by 2032, Driven by Rising Health & Plant-Based Demand
Vegan Dessert Market to Reach US$ 11.9 Bn by 2032, Driven by Rising Health & Pla …
Overview of the Market The global vegan dessert market is poised for significant expansion, with an estimated valuation of US$ 5.2 billion in 2025, projected to reach US$ 11.9 billion by 2032. This robust growth reflects a compound annual growth rate (CAGR) of 11.7% during the forecast period from 2025 to 2032. Increasing consumer awareness about health, environmental sustainability, and ethical food consumption is driving the widespread adoption of vegan dessert
Instant Beverage Premix Market to Reach US$148.3 Bn by 2032 Driven by Convenience & Demand
Instant Beverage Premix Market to Reach US$148.3 Bn by 2032 Driven by Convenienc …
Overview of the Global Instant Beverage Premix Market The global instant beverage premix market has witnessed remarkable growth over the past decade, driven by evolving consumer lifestyles and increasing demand for convenient, ready-to-consume beverages. Instant beverage premixes, encompassing products such as instant coffee, tea, flavored drinks, protein powders, and nutritional supplements, cater to busy consumers seeking quick preparation without compromising on taste or nutritional value. These premixes have gained popularity across
Dermacosmetics Market to Reach US$ 87.3 Bn by 2032 at 7.4% CAGR: Persistence Market Research
Dermacosmetics Market to Reach US$ 87.3 Bn by 2032 at 7.4% CAGR: Persistence Mar …
The global dermacosmetics market, estimated at US$ 53 billion in 2025, is forecasted to witness a steady upward trajectory, expanding at a Compound Annual Growth Rate (CAGR) of 7.4% to reach US$ 87.3 billion by 2032. This surge is driven by a confluence of factors ranging from increasing consumer awareness and the rising incidence of skin conditions to a growing preference for advanced, dermatologist-backed skincare solutions. Dermacosmetics, a category that

All 5 Releases


More Releases for Melanoma

Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period? The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market? The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market? The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma. Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379 Key Players Analysis: • Pfizer Inc. • Bristol-Myers Squibb Company • Abbott Laboratories • Amgen, Inc. • Merck & Co., Inc. • Novartis AG • F. Hoffmann-La Roche Ltd • Sanofi S.A. • Qiagen NV • Sun Pharmaceutical Industries Ltd
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic